Dr. Wong on the Potential Role of Venetoclax in Relapsed/Refractory AL Amyloidosis


In Partnership With:

Sandy Wong, MD, discusses the potential role of venetoclax in relapsed/refractory light chain amyloidosis.

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the potential role of venetoclax (Venclexta) in relapsed/refractory light chain (AL) amyloidosis.

Many treatment options are available for patients with relapsed/refractory AL amyloidosis, Wong says. However, some agents are associated with increased toxicity compared with others.

Many of these drugs were taken from the multiple myeloma paradigm, explains Wong. However, treatment-related toxicities may be more significant in AL amyloidosis versus multiple myeloma as patients with AL amyloidosis tend to be frail with multi-organ damage.

The BCL-2 inhibitor venetoclax is approved in chronic lymphocytic lymphoma and acute myeloid leukemia, Wong says. Additionally, the agent is under investigation in multiple myeloma, specifically for patients with translocation(11;14).

About half of patients with AL amyloidosis present with t(11;14) at diagnosis. As such, venetoclax could be a viable treatment option for this subgroup of patients, concludes Wong.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
A panel of 4 experts on hematologic malignancies
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.